Prenatal inflammation-induced NF-κB dyshomeostasis contributes to renin-angiotensin system over-activity resulting in prenatally programmed hypertension in offspring

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Deng, Youcai ^a,b   Deng, Yafei ^a   He, Xiaoyan ^c   Chu, Jianhong ^d   Zhou, Jianzhi ^a   Zhang, Qi ^a   Guo, Wei ^a   Huang, Pei ^a   Guan, Xiao ^a   Tang, Yuan ^a   Wei, Yanling ^a   Zhao, Shanyu ^a   Zhang, Xingxing ^a,e   Wei, Chiming ^f   Namaka, Michael ^g   Yi, Ping ^h   Yu, Jianhua ^h   Li, Xiaohui ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c Central Hospital of Jiangjin District   (China)

^d SOOCHOW UNIVERSITY   (China)

^e Department of Pharmacy   (China)

^f CHONGQING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g UNIVERSITY OF MANITOBA   (Canada)

^h THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE;

ANIMAL; COMPLICATION; FEMALE; HYPERTENSION; INFLAMMATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT;

ANIMALS; FEMALE; HYPERTENSION; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84958191354     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21692     Document Type: Conference Paper

References (56)

1. Barker, D., Barker, M., Fleming, T. & Lampl, M. Developmental biology: Support mothers to secure future public health. Nature 504, 209-11 (2013).
2. Laslett, L. J. et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 60, S1-49 (2012).
3. Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
4. Messerli, F. H., Williams, B. & Ritz, E. Essential hypertension. Lancet 370, 591-603 (2007).
5. Barker, D. J. The fetal origins of adult hypertension. J Hypertens Suppl 10, S39-44 (1992).
6. Gorgas, D. L. Infections related to pregnancy. Emerg Med Clin North Am 26, 345-66, viii (2008).
7. Safir, A., Levy, A., Sikuler, E. & Sheiner, E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 30, 765-70 (2010).
8. de Steenwinkel, F. D. et al. Circulating maternal cytokines influence fetal growth in pregnant women with rheumatoid arthritis. Ann Rheum Dis 72, 1995-2001 (2013).
9. Barker, D. J., Forsen, T., Eriksson, J. G. & Osmond, C. Growth and living conditions in childhood and hypertension in adult life: a longitudinal study. J Hypertens 20, 1951-6 (2002).
10. Eriksson, J., Forsen, T., Tuomilehto, J., Osmond, C. & Barker, D. Fetal and childhood growth and hypertension in adult life. Hypertension 36, 790-4 (2000).
11. Gaillard, R., Steegers, E. A., Tiemeier, H., Hofman, A. & Jaddoe, V. W. Placental vascular dysfunction, fetal and childhood growth, and cardiovascular development: The generation R study. Circulation 128, 2202-10 (2013).
12. Oliver, R. S. & Lamont, R. F. Infection and antibiotics in the aetiology, prediction and prevention of preterm birth. J Obstet Gynaecol 33, 768-75 (2013).
13. Desseauve, D. et al. Prevalence and risk factors of bacterial vaginosis during the first trimester of pregnancy in a large French population-based study. Eur J Obstet Gynecol Reprod Biol 163, 30-4 (2012).
14. Lien, E. et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105, 497-504 (2000).
15. Wei, Y. L., Li, X. H. & Zhou, J. Z. Prenatal exposure to lipopolysaccharide results in increases in blood pressure and body weight in rats. Acta Pharmacol Sin 28, 651-656 (2007).
16. Hao, X. Q. et al. Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats. Hypertens Res 33, 76-82 (2010).
17. Wei, Y. et al. Prenatal exposure to lipopolysaccharide results in myocardial remodelling in adult murine offspring. J Inflamm (Lond) 10, 35 (2013).
18. Zhao, S., Zhang, H., Cao, D., Liu, Y. & Li, X. Lipopolysaccharide exposure during pregnancy leads to aortic dysfunction in offspring rats. Plos One 9, e102273 (2014).
19. Safar, M. E., Levy, B. I. & Struijker-Boudier, H. Current Perspectives on Arterial Stiffness and Pulse Pressure in Hypertension and Cardiovascular Diseases. Circulation 107, 2864-2869 (2003).
20. Laurent, S. et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 34, 1203-6 (2003).
21. Mattace-Raso, F. U. et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113, 657-63 (2006).
22. Kaess, B. M. et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308, 875-81 (2012).
23. Zhao, S., Liu, Y. & Li, X. Effect of maternal lipopolysaccharides exposure during pregnancy on vascular structure in neonatal offspring rats. Zhonghua Xin Xue Guan Bing Za Zhi 42, 498-503 (2014).
24. Smale, S. T. Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol Rev 246, 193-204 (2012).
25. Hao, X. Q., Kong, T., Zhang, S. Y. & Zhao, Z. S. Alteration of embryonic AT(2)-R and inflammatory cytokines gene expression induced by prenatal exposure to lipopolysaccharide affects renal development. Exp Toxicol Pathol 65, 433-9 (2013).
26. Burnier, M. & Brunner, H. R. Angiotensin II receptor antagonists. Lancet 355, 637-45 (2000).
27. Ghiadoni, L., Taddei, S. & Virdis, A. Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol 10, 42-60 (2012).
28. Bader, M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50, 439-65 (2010).
29. Jandeleit, K., Perich, R., Jackson, B. & Johnston, C. I. Mesenteric resistance and brain microvascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 19, 348-52 (1992).
30. He, X. Y. et al. [Prenatal exposure to lipopolysaccharide results in vascular renin-angiotensin system dysfunction in offspring rats]. Zhonghua Xin Xue Guan Bing Za Zhi 39, 853-6 (2011).
31. Schreck, R., Meier, B., Mannel, D. N., Droge, W. & Baeuerle, P. A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175, 1181-94 (1992).
32. Liu, S. F., Ye, X. & Malik, A. B. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100, 1330-7 (1999).
33. Romashkova, J. A. & Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86-90 (1999).
34. Beraud, C., Henzel, W. J. & Baeuerle, P. A. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 96, 429-34 (1999).
35. Lee, K. H., Jeong, J. & Yoo, C. G. Long-term incubation with proteasome inhibitors (PIs) induces IkappaBalpha degradation via the lysosomal pathway in an IkappaB kinase (IKK)-dependent and IKK-independent manner. J Biol Chem 288, 32777-86 (2013).
36. Cheng, Q. et al. NK-kappa B subunit-specific regulation of the I kappa B alpha promoter. J Biol Chem 269, 13551-13557 (1994).
37. Waki, H., Gouraud, S. S., Maeda, M., Raizada, M. K. & Paton, J. F. Contributions of vascular inflammation in the brainstem for neurogenic hypertension. Respir Physiol Neurobiol 178, 422-8 (2011).
38. Dinh, Q. N., Drummond, G. R., Sobey, C. G. & Chrissobolis, S. Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension. Biomed Res Int 2014, 406960 (2014).
39. Hoffmann, A., Levchenko, A., Scott, M. L. & Baltimore, D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298, 1241-5 (2002).
40. Elks, C. M. et al. Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol 296, F298-305 (2009).
41. Rodriguez-Iturbe, B. et al. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 315, 51-7 (2005).
42. Gupta, S., Young, D. & Sen, S. Inhibition of NF-κB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289, H20-H29 (2005).
43. Malek, S., Chen, Y., Huxford, T. & Ghosh, G. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 276, 45225-35 (2001).
44. Tam, W. F. & Sen, R. IkappaB family members function by different mechanisms. J Biol Chem 276, 7701-4 (2001).
45. Arenzana-Seisdedos, F. et al. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 15, 2689-96 (1995).
46. Rao, P. et al. IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 466, 1115-9 (2010).
47. Scheibel, M. et al. IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo. J Exp Med 207, 2621-30 (2010).
48. Rosenbaugh, E. G., Savalia, K. K., Manickam, D. S. & Zimmerman, M. C. Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 304, R917-28 (2013).
49. Pacurari, M., Kafoury, R., Tchounwou, P. B. & Ndebele, K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014, 689360 (2014).
50. Brasier, A. R., Jamaluddin, M., Han, Y., Patterson, C. & Runge, M. S. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212, 155-69 (2000).
51. Han, Y., Runge, M. S. & Brasier, A. R. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84, 695-703 (1999).
52. Higuchi, S. et al. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112, 417-28 (2007).
53. Liao, J. K. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest 123, 540-1 (2013).
54. Mancini, G. B. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94, 258-65 (1996).
55. Deng, Y. et al. The Natural Product Phyllanthusmin C Enhances IFN-gamma Production by Human NK Cells through Upregulation of TLR-Mediated NF-kappaB Signaling. J Immunol 193, 2994-3002 (2014).
56. Deng, Y. et al. Transcription factor foxo1 is a negative regulator of natural killer cell maturation and function. Immunity 42, 457-70 (2015).